This Dividend King Just Announced Great News for Investors

Abbott (ABT) delivered Q3 2026 results showing 7% sales growth and 9% higher adjusted EPS, and paired the print with a structural move: a planned spin-off of its nutrition business into a standalone company.

The nutrition unit is described as struggling. Separating it removes a drag from the consolidated story. Our interpretation: investors may now value ABT more on its medical device mix, though the market's verdict on the spin remains to be seen.

The growth narrative centers on medical devices. FreeStyle Libre, the company's diabetes care franchise, anchors that segment. Abbott also completed the acquisition of Exact Sciences, extending its reach into cancer diagnostics. Together, these give the company two named growth vectors beyond the business being carved out.

For income-focused holders, ABT carries Dividend King status, with more than 50 consecutive years of dividend increases. That track record sits alongside the earnings growth, a combination that supports the stock's defensive profile.

Interpretation: a 9% adjusted EPS gain outpacing 7% sales growth points to margin or earnings leverage, though the source does not break out the drivers.